LETTERS TO THE EDITOR

Mutation of CDKN2 is infrequently detected in myelodysplastic syndrome
TO THE EDITOR Myelodysplastic syndrome (MDS) is characterized as a hematopoietic disorder that often results in bone marrow failure or overt leukemia. 1 We recently reported a patient showing loss of heterozygosity at AFM186Xc3 on chromosome 9p21 in our study on microsatellite instability in MDS. 2 Since this locus is very closely located proximal to the CDKN2 gene, also referred to as p16, which negatively regulates cell cycle through inhibition of cyclin-dependent kinase 4, 3, 4 we speculated that CDKN2 might play a role in the development or progression of MDS. Thus, we screened 45 patients with MDS for a point mutation of the CDKN2. We performed polymerase chain reaction mediated single strand conformation polymorphism (PCR-SSCP) to detect point mutations in exon 1 and 2 as described, 5 which correspond to 97% of CDKN2 coding sequences. SSCP analyses were carried out under various conditions, ie 5 or 10% glycerol concentration of the polyacrylamide gels, and electrophoresis at 4°C or room temperature, to avoid overlooking mutations. Moreover, the fragment containing exon 2 was cleaved into two shorter than 300 bases to showed normal SSCP pattern. However, another patient (case 530) who progressed to overt leukemia (M6) within 2 months from refractory anemia with excess of blasts in transformation (RAEB-t) showed a mobility shift in the SSCP analysis ( Figure 1a) . Sequencing analysis revealed a 2-base deletion at codon 58 (CAC→C) which generates a stop codon at codon 110, resulting in a 39 amino acids shorter CDKN2 protein ( Figure 2 ). Retrospective analysis confirmed the abnormal SSCP band in the sample at the initial presentation of MDS ( Figure 1a ). Ogawa et al 7 found no mutation of CDKN2 in six MDS patients examined and Quesnel et al 8 also failed to detect any mutation in 30 MDS patients.
To our knowledge, this is the first reported case of MDS harboring a CDKN2 mutation. Moreover, a 5-base deletion (CCTCC) involving codons 89 and 90 in exon 4 of the TP53 gene was also detected in the same DNA sample at diagnosis according to our previously reported method 9 (Figures 1b and  2 ). This mutation results in a truncated TP53 protein through a novel stop codon at codon 146. 
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10 and another one between RB and CDKN2 11 have a cell-cycle inhibitory effect by binding to cyclin-dependent kinases. Our present results suggest that both of the TP53-H Kaneko 
